New IPO Alert: Hindustan Laboratories files DRHP with SEBI to raise funds via public offer

Hindustan Laboratories IPO: Pharma player Hindustan Laboratories has filed preliminary papers with the market regulator, the Securities and Exchange Board of India (SEBI), to raise funds through an initial public offering.

The proposed initial share sale will be a mix of fresh issuance of 5,000,000 equity shares and an offer for sale (OFS) of 9,100,000 shares by promoter Rajesh Vasantray Doshi.

The funds generated will be allocated for funding working capital requirements and general corporate purposes.

"In addition, our company expects to receive the benefits of listing of the equity shares on the stock exchanges and enhancement of our company’s brand name amongst our existing and potential customers and creation of a public market for our equity shares in India," according to the draft red herring prospectus (DRHP).

The company will reserve 50% of the net offer for qualified institutional buyers (QIBs), 35% for retail investors and the remaining 15% for non-institutional investors.

Choice Capital Advisors is the issue's book-running lead manager, while MUFG Intime India Pvt is the registrar.

The company's shares will be listed on the National Stock Exchange (NSE) and the BSE.

Hindustan Laboratories is a pharmaceutical company engaged in the large-scale production and supply of generic medicines to government institutions under a business-to-government (B2G) model. Its products are usually generic formulations, which are medicines for which the patents have expired. They are typically utilised as a substitute for other expensive branded medicines.

Its product portfolio encompasses an array of therapeutic segments serving both acute and chronic healthcare needs. These include anti-diabetic, anti-infective, anti-allergic, anti-malarial, blood-related, cardiac, gastrointestinal, keratolytic, antiparasitic, pain and analgesic, nutritional and mineral supplements, respiratory nutritional and mineral supplements and vitamin supplements.

With comprehensive formulation capabilities, it offers customers a wide variety of dosage forms, such as capsules, tablets, powders, topical solutions, creams, oral liquids, ointments, combination blister packages and topical powders. Its product portfolio expanded from 661 products in March 2023 to 871 products in March 2025.